Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin and Tislelizumab in Advanced Solid Tumors
NCT07703163Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of canagliflozin in solid tumor, sponsored by West China Hospital of Sichuan University. Primary endpoint: Treatment-Emergent Adverse Events at 1 year. Started Sep 2026; status: recruiting.
02
Drugs
canagliflozin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07703163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07703163.